BCS CLASSIFICATION, CLINICAL TRIALS, AND DRUG DEVELOPMENT: A TEACHER’S COMPREHENSIVE GUIDE
Welcome, future pharmacists and pharmaceutical scientists!
The journey of a drug from discovery to the patient’s bedside is one of the most complex and regulated processes in the pharmaceutical industry. Understanding the Biopharmaceutics Classification System (BCS), clinical trials, drug development pathways, and intellectual property rights is essential for every pharmacist. This knowledge forms the foundation of how medicines are developed, tested, approved, and protected.
As a pharmacy educator with years of experience teaching pharmaceutical sciences and regulatory affairs, I have observed that students often find these topics challenging due to their technical nature. In this comprehensive guide, I will break down these concepts into manageable sections, explaining the BCS system, drug development stages, clinical trials, regulatory pathways, and intellectual property rights. Let us begin our journey.
Dpharmguru’s exam insights:
BCS classification, clinical trials, and drug development are frequently tested in pharmacy exams. Remember: BCS Class I (High Solubility-High Permeability), Class II (Low Solubility-High Permeability), Class III (High Solubility-Low Permeability), and Class IV (Low Solubility-Low Permeability). Drug development has five stages: Discovery, Pre-clinical, Clinical, FDA Review, and Post-marketing. NDA is for new drugs, ANDA is for generic drugs. Pay special attention to these distinctions—they are almost always asked in exams!
BCS SYSTEM OF CLASSIFICATION
The Biopharmaceutics Classification System (BCS) is a fundamental guideline for determining the conditions under which In-Vitro In-Vivo Correlations (IVIVC) are expected. BCS is also used as a tool for developing in-vitro dissolution specifications. The BCS for correlating in-vitro drug product dissolution and in-vivo bioavailability is proposed based on recognising that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling the rate and extent of drug absorption.
BCS Classification of Drugs
The drugs as per the BCS are divided into the following high/low-solubility and permeability classes:
- Class I (High Solubility-High Permeability Drugs): The drugs of this class behave like oral solutions having fast dissolution and rapid bioavailability. The dissolution and absorption of these drugs is very fast, thus bioavailability and bioequivalence are unnecessary for such drug products.
- Class II (Low Solubility-High Permeability Drugs): The drugs of this class have low solubility and high permeability, hence the dissolution rate becomes the rate-limiting step for bioavailability. These drugs have variable bioavailability, which can be improved by enhancing their dissolution rate by different methods.
- Class III (High Solubility-Low Permeability Drugs): Permeation through the intestinal membrane is the rate-limiting step for the drugs of this class. Since absorption is permeation rate-limited, bioavailability is independent of drug release from the dosage form. The drugs of Class III have low bioavailability and their permeability needs to be enhanced.
- Class IV (Low Solubility-Low Permeability Drugs): The drugs of this class have poor and variable bioavailability. These drugs are not considered as suitable candidates for oral drug delivery; if used, some special drug delivery technologies (such as nanosuspensions) are needed.
Dpharmguru’s exam insights:
BCS classification is frequently tested. Remember the four classes: Class I (High-High) behaves like oral solutions; Class II (Low-High) dissolution is rate-limiting; Class III (High-Low) permeation is rate-limiting; Class IV (Low-Low) has poor bioavailability. Also remember that Class I drugs may qualify for biowaivers!
BCS CLASSIFICATION SUMMARY TABLE
| Class | Solubility | Permeability | Rate-Limiting Step | Bioavailability |
|---|---|---|---|---|
| Class I | High | High | Drug dissolution | Rapid and complete |
| Class II | Low | High | Dissolution rate | Variable |
| Class III | High | Low | Permeation rate | Low |
| Class IV | Low | Low | Both dissolution and permeation | Poor and variable |
NEW DRUG DEVELOPMENT
Drug development is the process which comprises marketing of a new pharmaceutical drug after the identification of a lead compound by the drug discovery process. It includes pre-clinical studies on animals and filing the investigational new drug application to initiate clinical trials.
Stages of New Drug Development
1. Discovery and Development
Drug discovery is the process of discovering new medications. In ancient times, drugs were mostly discovered by identifying active ingredients from traditional medication or by chance. Nowadays, screening hits, medicinal chemistry, and optimization of hits to decrease possible side effects while increasing affinity and selectivity are part of drug discovery.
2. Pre-clinical Studies
Drug development starts with preclinical research to regulate the efficacy and safety of the drug once a lead compound is found. For efficacy, toxicity, and pharmacokinetic information, preclinical trials are performed on non-human subjects.
Properties determined by researchers:
- Absorption, distribution, metabolism, and excretion (ADME) information
- Potential benefits and mechanisms of action
- Best dosage and administration route
- Side effects/adverse events
- Effects on gender, race, or ethnicity groups
- Interaction with other treatments
- Effectiveness compared to similar drugs
3. Clinical Studies
Researchers move on to clinical drug development, including clinical trials and volunteer studies after preclinical research is completed. Clinical trial design and associated costs may affect trials carried out during this phase.
4. FDA Drug Review
After testing efficacy and safety of the new drug and the results are available from clinical trials, it is forwarded for wholistic FDA review. At this time, the drug application is reviewed and may be approved or not approved by the FDA.
5. Post-marketing Drug Safety Monitoring
The FDA requires drug companies to monitor the safety of its drug using the FDA Adverse Event Reporting System (FAERS) database following drug approval. Manufacturers, health professionals, and consumers report problems with approved drugs through this program.
Dpharmguru’s exam insights:
The five stages of drug development are frequently tested. Remember: (1) Discovery and Development, (2) Pre-clinical Studies, (3) Clinical Studies, (4) FDA Review, (5) Post-marketing Monitoring. Pre-clinical studies determine ADME, dosage, and side effects. Post-marketing monitoring uses FAERS database!
ABBREVIATED NEW DRUG APPLICATION (ANDA)
An Abbreviated New Drug Application (ANDA) includes data submitted to the FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to offer a safe, effective, lower-cost alternative to the brand-name drug.
Generic drug applications are normally not required to include preclinical and clinical data to establish safety and effectiveness—that is why they are termed as “abbreviated”.
Objectives of ANDA
- To check whether the benefits of the drug outweigh the risks and whether the drug is safe and effective in its proposed use.
- To check whether the drug’s proposed labelling is appropriate.
- To check whether the controls used to preserve the drug’s quality are adequate.
- To reduce the price of the drug.
- To reduce the time of development.
- To increase the bioavailability of the drug in comparison to the reference listed drug.
Patent Certifications
- Para I Certification: No patent listed
- Para II Certification: Patent expired
- Para III Certification: Patent valid but generic marketed after expiry
- Para IV Certification: Patent challenged by generic manufacturer
Dpharmguru’s exam insights:
ANDA is frequently tested. Remember: ANDA is for generic drugs; no clinical trials required; Para IV certification is a patent challenge; objectives include reducing price and development time. The term “abbreviated” refers to the absence of clinical data!
NEW DRUG APPLICATION (NDA)
A new drug can be an established medication prescribed for use in a new way or a novel chemical formula that has not been deemed safe and effective by certified professionals. The New Drug Application (NDA) is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.
Objectives of NDA
- To determine whether the drug is safe and effective.
- To check whether proposed labelling is appropriate.
- To ensure manufacturing methods maintain identity, strength, quality, and purity.
NDA Approval Process
- Pre-NDA Meeting: Addresses NDA submission details.
- NDA Submission & Review: Formal application submitted.
- File Acceptance (60-Day Window): FDA decides whether to accept for full review.
- CDER Eligibility Evaluation: Application sent to Center for Drug Evaluation and Research.
- Facility Inspection: FDA inspects manufacturing facilities.
- Reviewer Team Report (180-Day Window): Team submits final report to CDER.
- Marketing Authorisation: FDA issues marketing authorisation.
Dpharmguru’s exam insights:
NDA is frequently tested. Remember: NDA is for new drugs; requires clinical data; FDA has 60 days for file acceptance; 180 days for review; CDER is the Center for Drug Evaluation and Research. The NDA process is more complex than ANDA!
CLINICAL TRIALS
Clinical trials are research projects in which participants volunteer to aid in the search for solutions to particular health-related issues. They are the quickest and safest method for identifying novel therapies and strategies to enhance health when done appropriately.
Phases of Clinical Trials
- Phase I: Determines a safe dose range and locates adverse effects by testing new medications on a limited number of volunteers (20-80 subjects).
- Phase II: Investigates the medical procedures that were deemed safe in Phase I on a wider population (100-300 subjects) to watch for adverse effects.
- Phase III: Carried out on bigger populations (1,000-3,000 subjects) and in various locations and countries, conducted just before drug approval.
- Phase IV: Conducted following national approval, with more extensive testing over a longer period of time (post-marketing surveillance).
Dpharmguru’s exam insights:
Clinical trial phases are frequently tested. Remember: Phase I (20-80 subjects, safety); Phase II (100-300, efficacy); Phase III (1,000-3,000, confirm); Phase IV (post-marketing surveillance). The number of subjects in each phase is often asked in exams!
NEW DRUGS AND CLINICAL TRIALS RULES, 2019
The New Drugs and Clinical Trials Rules, 2019 have been released by India’s Ministry of Health and Family Welfare (MoHFW). In addition to difficult subjects such as orphan drugs, post-trial access, and pre- and post-submission meetings, the new laws also include provisions for boosting clinical research.
New Definitions in NDCT Rules, 2019
- Academic Clinical Trial: A clinical trial initiated by an investigator or academic institution for a new indication, route, dose, or dosage form, with results intended for academic purposes and not for seeking approval.
- Biomedical and Health Research: Research designed to increase scientific knowledge about diseases and conditions but does not include clinical trials.
- Orphan Drug: A drug intended to treat a condition which affects not more than five lakh persons in India.
- Post-trial Access: Making a new drug or investigational new drug available to a trial subject after completion of a clinical trial through which the drug has been found beneficial.
NDCT Rules, 2019 are frequently tested. Remember: Orphan drug affects not more than 5 lakh persons in India; Academic clinical trials are for research purposes only; Post-trial access provides continued access to beneficial drugs. The rules have 13 chapters and 8 schedules!
BRAND NAME VS GENERIC DRUGS
| Feature | Generic Drugs | Brand Name Drugs |
|---|---|---|
| Definition | Off-patent pharmaceutical product manufactured after patent expiry | Developed and marketed under a patent or trademark |
| Patent | Off patent | Patent protected |
| Trade Name | Marketed under generic name | Unique proprietary name |
| Application | ANDA required | NDA required |
| Manufactured By | Several companies after patent expiry | Innovator company |
| Clinical Trials | Not required | Essential to perform |
| Price | Cheaper | Costly |
| Appearance | Different colour, shape, and size | Unique look |
Dpharmguru’s exam insights:
Brand vs Generic is frequently tested. Remember: Generic drugs are identical in active ingredients, strength, dosage form, and route of administration; they differ in appearance, colour, shape, and taste; generic drugs are cheaper because no clinical trials are required; ANDA is for generic, NDA is for brand.
INTELLECTUAL PROPERTY RIGHTS (IPRs)
Intellectual property is considered like any other commercial property which could be possessed, used, enjoyed, or disposed of by its legal owner. All rights originating from the legal protection granted to the possessors, creators, or owners of intellectual property are referred to as intellectual property rights.
Forms of IPRs
-
- Patents: Grants inventors an exclusive right to prevent others from using their inventions without permission.
-
- Trademarks: Distinctive signs that help consumers identify the source of specific goods or services.
-
- Copyrights: Rights for developing original works in literature, art, music, or drama.
-
- Trade Secrets: Practices, formulas, traditions, or methods that are concealed to gain a competitive edge.
-
- Franchising: Agreement where the owner grants the right to use its trade name or trademark.
-
- Licensing: Allows business expansion, quality enhancement, and improvement in market position.
Importance of IPRs in Pharmaceutical Companies
-
- Protects invention through patents and trade secrets.
-
- Accelerates economic growth and competitiveness.
-
- Protects consumers and families by ensuring safety and quality.
-
- Protects against potential infringement of drug discovery.
Dpharmguru’s exam insights:
IPRs are frequently tested. Remember: Patents protect inventions; trademarks protect brands; copyrights protect original works; trade secrets protect confidential information. In India, patent rights are governed by the Patents Act, 1970. The patent term is 20 years!
PATENTS
An exclusive and absolute right granted to the owner or inventor of an invention to create, utilise, produce, and market the invention is termed as a patent. Such rights are awarded by the country for a limited time period, presuming that the invention fulfils all the conditions specified in the law.
Conditions of Patentability
-
- Novelty: The invention must be new and not already part of existing knowledge.
-
- Non-Obvious: The invention must be non-obvious to experts in the field.
-
- Useful and Industrially Applicable: The invention must be beneficial and industrially applicable.
Term of Patent
For all types of products, the validity of a patent is 20 years from the date on which the patent application is filed.
Dpharmguru’s exam insights:
Patent conditions are frequently tested. Remember: Novelty, Non-Obvious, and Utility are the three conditions; patent term is 20 years; renewal fee must be paid every year; restoration can be requested within 18 months of cessation. Indian Patent Law is governed by the Patents Act, 1970.
EMERGENCY USE AUTHORISATION (EUA)
Emergency Use Authorisation (EUA) is an authorisation issued for unregistered drugs and vaccines in a public health emergency. The FDA may determine that it is appropriate to release something for use in declared emergencies even in the lack of complete information supporting its efficacy and safety.
Conditions for Issuing EUA
-
- The agent may result in a serious or life-threatening illness.
-
- It is reasonable to assume the product may be useful.
-
- The known and potential benefits outweigh the known and potential risks.
-
- The product is the only suitable, authorised, and accessible option.
Dpharmguru’s exam insights:
EUA is frequently tested, especially in the context of COVID-19. Remember: EUA allows use of unapproved drugs during emergencies; benefits must outweigh risks; the FDA publishes notice of each EUA in the Federal Register. COVID-19 vaccines like Pfizer-BioNTech and Covaxin were issued EUAs!
FREQUENTLY ASKED QUESTIONS (FAQs)
1. What is the BCS classification system?
BCS classifies drugs based on their solubility and permeability into four classes: Class I (High-High), Class II (Low-High), Class III (High-Low), and Class IV (Low-Low).
2. What is the difference between NDA and ANDA?
NDA is for new brand drugs and requires clinical data; ANDA is for generic drugs and does not require clinical data. NDA is more complex and expensive than ANDA.
3. What are the phases of clinical trials?
Phase I (20-80 subjects, safety), Phase II (100-300, efficacy), Phase III (1,000-3,000, confirm), Phase IV (post-marketing surveillance).
4. What is an orphan drug?
An orphan drug is a drug intended to treat a condition which affects not more than five lakh persons in India, as defined under the NDCT Rules, 2019.
5. What is the term of a patent in India?
The validity of a patent is 20 years from the date on which the patent application is filed.
6. What is Emergency Use Authorisation?
EUA is an authorisation issued for unregistered drugs and vaccines in a public health emergency when the known and potential benefits outweigh the risks.
7. What are the patent certifications under ANDA?
Para I (No patent listed), Para II (Patent expired), Para III (Patent valid but generic after expiry), Para IV (Patent challenged by generic manufacturer).
SUMMARY
The Biopharmaceutics Classification System (BCS) classifies drugs into four classes based on solubility and permeability. Class I drugs have high solubility and high permeability; Class II have low solubility and high permeability; Class III have high solubility and low permeability; Class IV have low solubility and low permeability.
Drug development involves five stages: Discovery, Pre-clinical Studies, Clinical Studies, FDA Review, and Post-marketing Surveillance. NDA is required for new drugs, while ANDA is required for generic drugs. Clinical trials are conducted in four phases, each with specific objectives and subject numbers.
The New Drugs and Clinical Trials Rules, 2019 introduced important provisions for orphan drugs, post-trial access, and academic clinical trials. Intellectual Property Rights protect pharmaceutical innovations through patents, trademarks, copyrights, and trade secrets. Emergency Use Authorisation allows the use of unapproved drugs during public health emergencies.
As I always tell my students: “The journey from drug discovery to patient care is long and complex, but every step is essential to ensure safety, efficacy, and quality. Understanding this journey makes us better pharmacists and better advocates for public health.”
REFERENCES AND FURTHER READING
-
- U.S. Food and Drug Administration (FDA). (2022). New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) Guidelines. Retrieved from https://www.fda.gov.
-
- World Health Organization (WHO). (2022). Biopharmaceutics Classification System Guidelines. Retrieved from https://www.who.int.
-
- Ministry of Health and Family Welfare. (2019). New Drugs and Clinical Trials Rules, 2019. Government of India.
-
- Patents Act, 1970. Government of India.
-
- International Conference on Harmonisation (ICH). (2022). Guidelines on Clinical Trials and Drug Development. Retrieved from https://www.ich.org.
Disclaimer: This article is for educational purposes only and does not constitute legal or medical advice. Drug development, clinical trials, and regulatory requirements may change over time—always refer to the latest official guidelines and consult qualified professionals for specific matters.
written by:
Dr. N. Sujith Kumar
For More Study Materials, Visit: www.dpharmguru.com
